Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Zhang, L.; Bolomsky, A.; Al Odat, O. S.; VanWinkle, C.; Battle, A.; Chakraborty, P.; Holewinski, R. J.; Meng, Q.; Phelan, J. D.; Muppidi, J.; Young, R. M.
Show abstract
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but how they signal is less well characterized than in carcinomas. To uncover novel RAS biology and potential therapeutic vulnerabilities, we employed a multi-omics screening approach in multiple myeloma to identify regulators of RAS activity. We report that the phosphatase PP1C dephosphorylates the conserved T148 residue on RAS, which in turn permits LZTR1-dependent proteasomal degradation. Notably, LZTR1 is ineffective against KRAS A146 gain-of-function mutations, which are adjacent to T148 and prevalent in hematologic cancers. Remarkably, we find that KRAS protein is four-fold less stable in hematologic versus carcinoma cells, offering a unique therapeutic opportunity targeting RAS protein stability mechanisms. The kinases PAK1 and PAK2 shield RAS from LZTR1-dependent degradation by phosphorylating T148, and targeting PAK1/2 activity improves RAS-directed therapy. Collectively, our findings reveal a novel regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Aberrant non-canonical NF-kappaB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma 96%
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer 96%
- Cell polarity proteins promote macropinocytosis in response to metabolic stress 96%
Similar papers in this journal
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 96%
- PAX3-FOXO1 drives targetable cell state-dependent metabolic vulnerabilities in rhabdomyosarcoma 96%
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 94%
Similar papers in this journal
- Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 95%
- Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy 94%
- FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer 94%
Similar papers in this journal
Similar papers in this journal
- Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma 96%
- Metabolic regulation of RNA methylation by the m6A-reader IGF2BP3 96%
- NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.